You can buy or sell CALT and other stocks, options, and ETFs commission-free!
Calliditas Therapeutics AB provides pharmaceutical products for patients with niche indications. It focuses on development and commercialization of the product candidate Nefecon intended for treatment of patients with the inflammatory renal disease IgA nephropathy. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden. The listed name for CALT is Calliditas Therapeutics AB American Depositary Shares.
Renée Julie Elisabet Aguiar-Lucander
52 Week High
52 Week Low
— per share
Available Feb 18, Pre-Market